

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 0 574 466 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention
of the grant of the patent:
19.05.1999 Bulletin 1999/20

(21) Application number: 92905914.5

(22) Date of filing: 05.03.1992

(51) Int Cl.⁶: **C12N 15/74**, C12N 15/70,
C12N 15/31, A61K 39/112,
A61K 39/10, C12N 1/21
// (C12N1/21, C12R1:42)

(86) International application number:
PCT/GB92/00387

(87) International publication number:
WO 92/15689 (17.09.1992 Gazette 1992/24)

(54) **EXPRESSION OF RECOMBINANT PROTEINS IN ATTENUATED BACTERIA**

EXPRESSION REKOMBINANTER PROTEINE IN ATTENUIERTEN BAKTERIEN

EXPRESSION DE PROTEINES DE RECOMBINAISON DANS DES BACTERIES ATTENUÉES

(84) Designated Contracting States:
AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE

(30) Priority: 05.03.1991 GB 9104596
04.10.1991 GB 9121208

(43) Date of publication of application:
22.12.1993 Bulletin 1993/51

(73) Proprietor: **THE WELLCOME FOUNDATION
LIMITED**
Greenford, Middlesex UB6 0NN (GB)

(72) Inventors:
• **CHARLES, Ian George**
Beckenham, Kent BR3 3BS (GB)
• **CHATFIELD, Steven Neville**
Beckenham, Kent BR3 3BS (GB)
• **FAIRWEATHER, Neil Fraser**
Beckenham, Kent BR3 3BS (GB)

(74) Representative: **Woods, Geoffrey Corlett et al**
J.A. KEMP & CO.
14 South Square
Gray's Inn
London WC1R 5LX (GB)

(56) References cited:

EP-A- 0 285 152 EP-A- 0 322 237
EP-A- 0 357 208 EP-A- 0 400 958

- RES. MICROBIOL. vol. 141, no. 7-8, 1990, INSTITUT PASTEUR, ELSEVIER, PARIS; pages 769 - 773; N.F. FAIRWEATHER ET AL.: "Use of live attenuated bacteria to stimulate immunity" International symposium on oral immunization using recombinant bacteria, Munich, Germany, June 6-7, 1990
- INFECTION AND IMMUNITY vol. 58, no. 5, May 1990, AM. SOC. MICROBIOL., BALTIMORE, US; pages 1323 - 1326; N.F. FAIRWEATHER ET AL.: 'Oral vaccination of mice against tetanus by use of a live attenuated salmonella carrier'
- MOLEC. MICROBIOL. vol. 4, no. 10, October 1990, BLACKWELL SCI. PUB., OXFORD, UK; pages 1753 - 1763; A.I. BELL ET AL.: 'Molecular genetic analysis of an FNR- dependent anaerobically inducible escherichia coli promoter' cited in the application
- MOLEC. MICROBIOL. vol. 2, no. 4, April 1988, BLACKWELL SCI. PUB., OXFORD, UK; pages 527 - 530; P.S. JAYARAMAN ET AL.: 'The nlrB promoter of escherichia coli: location of nucleotide sequences essential for regulation by oxygen, the FNR protein and nitrite'

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 0 574 466 B1

EP 0 574 466 B1

Description

[0001] This invention relates to vaccines containing attenuated bacteria capable of expressing a heterologous protein.

[0002] Virulent strains of Salmonella can be attenuated by introducing specific mutations into genes required for survival and growth in vivo. Attenuated variants which establish self limiting, clinically insignificant infections can be considered as potential live oral vaccines against Salmonella infections. Ty21a is an attenuated variant of Salmonella typhi, which harbours mutations in galE and other unknown attenuating lesions, and is licensed for use in many countries as a live oral typhoid vaccine.

[0003] More recently genetically defined Salmonella strains harbouring individual specific mutants in different genes have been tested as experimental oral vaccines in several target species. For example, Salmonella aro mutants, which have an auxotrophic requirement for several aromatic compounds, have been shown to be effective oral vaccines in mice, sheep, cattle, chickens and more recently they have been shown to be attenuated and immunogenic in volunteers. Salmonella double aro mutants are disclosed in EP-A-0322237. Salmonella cya crp double mutants are also effective oral vaccines.

[0004] As well as being vaccines in their own right against salmonellosis, attenuated Salmonellae can be considered as carriers of heterologous antigens to the mucosal immune system. This is because Salmonellae can be delivered via the oral route and are potent immunogens being able to stimulate systemic and local cellular and antibody responses. Heterologous antigens from bacteria, viruses and parasites can be delivered to the host using Salmonella vaccines.

[0005] One potentially serious drawback in using these live vaccines for antigen delivery relates to problems with the stability of the foreign antigen expression in vivo. Unregulated expression of high levels of a foreign protein in bacteria from multiple copy plasmids usually results in rapid loss of the plasmid or expressed gene from the cells. This problem can be controlled in fermenters by using inducible promoter systems such as trp or lac to allow the controlled induction of gene expression when the appropriate biomass has been achieved. Obviously these promoters can not be induced by exogenously applied inducers such as PP or IPTG when bacteria are growing in host tissues during the self-limited growth following vaccination.

[0006] In vivo plasmid instability during vaccination with live bacterial vectors has in fact been reported by many workers (Maskell et al, Microb.Path 2, 295-305, 1987; Nakayama et al, Bio/technology 6, 693-697, 1988; Tite et al, Immunology 70, 540-546, 1990). A number of approaches have been taken to overcome the problem including the use of integration systems for expression of the heterologous antigen from the bacterial chromosome (Hone et al, Microbiol. Path. 5, 407-418, 1988; Strugnelli et al, Gene 88, 57-63, 1990). However, this approach is only suitable for use with some antigens since expression levels are often quite low (Maskell et al, 1987). Nakayama et al described the use of linking an essential gene to the expression plasmid for stabilizing in vivo expression. Although this is a highly effective approach, it does not prevent the generation of plasmid free variants but simply ensures they do not survive. Further, stable but constitutive high level expression of a foreign antigen in a Salmonella vaccine strain could slow down the growth rate and hence potentially effect the immunogenicity of the live vaccine.

According to the present invention, there is provided a vaccine comprising a pharmaceutically acceptable carrier or diluent and, as active ingredient, an attenuated bacterium which contains a promoter whose activity is induced by anaerobic conditions operably linked to a DNA sequence encoding a heterologous protein comprising an antigenic determinant of a pathogenic organism. Stable expression of the heterologous protein can be obtained in vivo.

[0007] Any suitable bacterium may be employed, for example a Gram-negative bacterium. Some Gram-negative bacteria such as Salmonella invade and grow within eucaryotic cells and colonise mucosal surfaces.

[0008] The attenuated bacterium may therefore be selected from the genera Salmonella, Bordetella, Vibrio, Haemophilus, Neisseria and Yersinia. Alternatively, the attenuated bacterium may be an attenuated strain of enterotoxigenic Escherichia coli. In particular the following species can be mentioned: S. typhi - the cause of human typhoid; S. typhimurium - the cause of salmonellosis in several animal species; S. enteritidis - a cause of food poisoning in humans; S. choleraesuis - a cause of salmonellosis in pigs; Bordetella pertussis - the cause of whooping cough; Haemophilus influenzae - a cause of meningitis; Neisseria gonorrhoeae - the cause of gonorrhoea; and Yersinia - a cause of food poisoning.

[0009] Attenuation of the bacterium may be attributable to a non-reverting mutation in a gene in the aromatic amino acid biosynthetic pathway of the bacterium. There are at least ten genes involved in the synthesis of chorismate, the branch point compound in the aromatic amino acid biosynthetic pathway. Several of these map at widely differing locations on the bacterial genome, for example aroA (5-enolpyruvylshikimate-3-phosphate synthase), aroC (chorismate synthase), aroD (3-dihydroquinate dehydratase) and aroE (shikimate dehydrogenase). A mutation may therefore occur in the aroA, aroC, aroD or aroE gene.

[0010] Preferably, however, an attenuated bacterium harbours a non-reverting mutation in each of two discrete genes in its aromatic amino acid biosynthetic pathway. Such bacteria are disclosed in EP-A-0322237. Double aro mutants which are suitable are aroA aroC, aroA aroD and aroA aroE mutant bacteria. Other bacteria having mutations in other

EP 0 574 466 B1

combinations of the aroA, aroC, aroD and aroE genes are however useful. Particularly preferred are Salmonella double aro mutants, for example double aro mutants of S.typhi or S.typhimurium, in particular aroA aroC, aroA aroD and aroA aroE mutants.

[0011] Alternatively, the attenuated bacterium may harbour a non-reverting mutation in a gene concerned with the regulation of one or more other genes (EP-A-0400958). Preferably the mutation occurs in the ompR gene or another gene involved in regulation. There are a large number of other genes which are concerned with regulation and are known to respond to environmental stimuli (Ronson *et al*, Cell 49, 579-581).

[0012] This type of attenuated bacterium may harbour a second mutation in a second gene. Preferably the second gene is a gene encoding for an enzyme involved in an essential biosynthetic pathway, in particular genes involved in the pre-chorismate pathway involved in the biosynthesis of aromatic compounds. The second mutation is therefore preferably in the aroA, aroC or aroD gene.

[0013] Another type of attenuated bacterium is one in which attenuation is brought about by the presence of a non-reverting mutation in DNA of the bacterium which encodes a protein that is produced in response to environmental stress, or in DNA of the bacterium which encodes a protein that regulates the expression of DNA encoding a protein that is produced in response to environmental stress. Such bacteria are disclosed in WO 91/15572. The non-reverting mutation may be a deletion, insertion, inversion or substitution. A deletion mutation may be generated using a transposon.

[0014] Examples of proteins that are produced in response to environmental stress include heat shock proteins (which are produced in response to a temperature increase above 42°C); nutrient deprivation proteins (which are produced in response to levels of essential nutrients such as phosphates or nitrogen which are below that which the microorganism requires to survive); toxic stress proteins (which are produced in response to toxic compounds such as dyes, acids or possibly plant exudates); or metabolic disruption proteins (which are produced in response to fluctuations in for example ion levels affecting the microorganisms ability to osmoregulate, or vitamin or co-factor levels such as to disrupt metabolism).

[0015] Preferably a heat shock protein is the one encoded by the htrA gene, also characterised as degP. Other proteins are encoded by genes known to be involved in the stress response such as grpE, groEL, (moPA), dnaK, groES, lon and dnaJ. There are many other proteins encoded by genes which are known to be induced in response to environmental stress (Ronson *et al*, Cell 49, 579-581). Amongst these the following can be mentioned: the ntrB/ntrC system of E. coli, which is induced in response to nitrogen deprivation and positively regulates glnA and nifLA (Buck *et al.*, Nature 320, 374-378, 1986; Hirschman *et al.*, Proc. Natl. Acad. Sci. USA, 82, 7525, 1985; Nixon *et al.*, Proc. Natl. Acad. Sci. USA 83, 7850-7854, 1986; Reitzer and Magasanik, Cell, 45, 785, 1986); the phoR/phoB system of E. coli which is induced in response to phosphate deprivation (Makino *et al.*, J. Mol. Biol. 192, 549-556, 1986b); the cpxA/sfrA system of E. coli which is induced in response to dyes and other toxic compounds (Albin *et al.*, J. Biol. Chem. 261 4698, 1986; Drury *et al.*, J. Biol. Chem. 260, 4236-4272, 1985). An analogous system in Rhizobium is dctB/dctD, which is responsive to 4C-discarboxylic acids (Ronson *et al.*, J. Bacteriol. 169, 2424 and Cell 49, 579-581, 1987). A virulence system of this type has been described in Agrobacterium. This is the virA/virG system, which is induced in response to plant exudates (le Roux *et al.*, EMBO J. 6, 849-856, 1987; Stachel and Zambryski, Am. J. Vet. Res 45, 59-66, 1986; Winans *et al.*, Proc. Natl. Acad. Sci. USA, 83, 8278, 1986). Similarly the bvgC-bvgA system in Bordetella pertussis (previously known as vir) regulates the production of virulence determinants in response to fluctuations in Mg2+ and nicotinic acid levels (Arico *et al.*, 1989, Proc. Natl. Acad. Sci. USA 86, 6671-6675).

[0016] For use in the form of a live vaccine, an attenuated bacterium should not revert back to the virulent state. The probability of this happening with a mutation in a single DNA sequence is considered to be small. However, the risk of reversion occurring with a bacterium attenuated by the presence of mutations in each of two discrete DNA sequences is considered to be insignificant. A preferred attenuated bacterium is therefore one in which attenuation is brought about (1) by the presence of a mutation in a DNA sequence which encodes a protein that is produced in response to environmental stress, or in a DNA sequence which encodes a protein that regulates the expression of DNA encoding a protein that is produced in response to environmental stress and (2) by the presence of a mutation in a second DNA sequence.

[0017] The second DNA sequence preferably encodes an enzyme involved in an essential auxotrophic pathway or is a sequence whose product controls the regulation of osmotically responsive genes, i.e. ompR, (Infect and Immun 1989 2136-2140). Most preferably, the mutation is in a DNA sequence involved in the aromatic amino acid biosynthetic pathway, more particularly the DNA sequences encoding aroA, aroC or aroD.

[0018] Attenuated bacteria may be constructed by the introduction of a mutation into the DNA sequence by methods known to those skilled in the art (Maniatis, Molecular Cloning and Laboratory Manual, 1982). Non-reverting mutations can be generated by introducing a hybrid transposon TnphoA into, for example, S.typhimurium strains. TnphoA can generate enzymatically active protein fusions of alkaline phosphatase to periplasmic or membrane proteins. The TnphoA transposon carries a gene encoding kanamycin resistance. Transductants are selected that are kanamycin resistant by growing colonies on an appropriate selection medium.

EP 0 574 466 B1

[0019] Alternative methods include cloning the DNA sequence into a vector, e.g. a plasmid or cosmid, inserting a selectable marker gene into the cloned DNA sequence, resulting in its inactivation. A plasmid carrying the inactivated DNA sequence and a different selectable marker can be introduced into the organism by known techniques (Maniatis, Molecular Cloning and Laboratory Manual, 1982). It is then possible by suitable selection to identify a mutant wherein the inactivated DNA sequence has recombined into the chromosome of the microorganism and the wild-type DNA sequence has been rendered non-functional in a process known as allelic exchange. In particular, the vector used is preferably unstable in the microorganism and will be spontaneously lost. The mutated DNA sequence on the plasmid and the wild-type DNA sequence may be exchanged by a genetic cross-over event. Additional methods eliminate the introduction of foreign DNA into vaccine strains at the site of mutations and the introduction of antibiotic resistant markers into the strains.

[0020] The heterologous antigen which an attenuated bacterium is capable of expressing comprises an antigenic determinant of a pathogenic organism. The antigen may be derived from a virus, bacterium, fungus, yeast or parasite. The heterologous protein therefore typically comprises an antigenic sequence derived from a virus, bacterium, fungus, yeast or parasite. More especially, the antigenic sequence may be derived from a type of human immunodeficiency virus (HIV) such as HIV-1 or HIV-2, hepatitis A or B virus, human rhinovirus such as type 2 or type 14, herpes simplex virus, poliovirus type 2 or 3, foot-and-mouth disease virus, influenza virus, coxsackie virus, the cell surface antigen CD4 and *Chlamydia trachomatis*. The antigen may comprise the CD4 receptor binding site from HIV, for example from HIV-1 or -2. Other useful antigens include *E. coli* heat labile toxin B subunit (LT-B), *E. coli* K88 antigens, P.69 protein from *B. pertussis*, tetanus toxin fragment C and antigens of flukes, mycoplasma, roundworms, tapeworms, rabies virus and rotavirus.

[0021] A preferred promoter for use in controlling the expression of the heterologous protein is the *nirB* promoter. The *nirB* promoter has been isolated from *E. coli*, where it directs expression of an operon which includes the nitrite reductase gene *nirB* (Jayaraman *et al.*, J. Mol. Biol. **196**, 781-788, 1987), and *nirD*, *nirC* and *cysG* (Peakman *et al.*, Eur. J. Biochem. **191**, 315-323, 1990). It is regulated both by nitrite and by changes in the oxygen tension of the environment, becoming active when deprived of oxygen (Cole, Biochim. Biophys. Acta, **162**, 356-368, 1968). Response to anaerobiosis is mediated through the protein FNR, acting as a transcriptional activator, in a mechanism common to many anaerobic respiratory genes.

[0022] By deletion and mutational analysis the part of the promoter which responds solely to anaerobiosis has been isolated and by comparison with other anaerobically-regulated promoters a consensus FNR-binding site was identified (Bell *et al.*, Nucl. Acids. Res. **17**, 3865-3874, 1989; Jayaraman *et al.*, Nucl. Acids Res. **17**, 135-145, 1989). It was also shown that the distance between the putative FNR-binding site and the -10 homology region is critical (Bell *et al.*, Molec. Microbiol. **4**, 1753-1763, 1990). It is therefore preferred to use only that part of the *nirB* promoter which responds solely to anaerobiosis. As used herein references to the *nirB* promoter refer to the promoter itself or a part or derivative thereof which is capable of promoting expression of a coding sequence under anaerobic conditions. The sequence which we have in fact used and which contains the *nirB* promoter is:

AATTCAGGTAAATTTGATGTACATCAAATGGTACCCCTTGCTGAATCGTTAAGGTA
GGCGGTAGGGCC

[0023] An attenuated bacterium used according to the present invention may be prepared by transforming an attenuated bacterium with a DNA construct comprising a promoter whose activity is induced by anaerobic conditions, such as the *nirB* promoter, operably linked to a DNA sequence encoding a heterologous protein. Any suitable transformation technique may be employed, such as electroporation. In this way, an attenuated bacterium capable of expressing a protein heterologous to the bacterium may be obtained. A culture of the attenuated bacterium may be grown under aerobic conditions. A sufficient amount of the bacterium is thus prepared for formulation as a vaccine, with minimal expression of the heterologous protein occurring.

[0024] The DNA construct is typically a replicable expression vector comprising the *nirB* promoter operably linked to a DNA sequence encoding the heterologous protein. The *nirB* promoter may be inserted in an expression vector, which already incorporates a gene encoding the heterologous protein, in place of the existing promoter controlling expression of the protein. The expression vector should of course be compatible with the attenuated bacterium into which the vector is to be inserted.

[0025] The expression vector is provided with appropriate transcriptional and translational control elements including, besides the *nirB* promoter, a transcriptional termination site and translational start and stop codons. An appropriate ribosome binding site is provided. The vector typically comprises an origin of replication and, if desired, a selectable marker gene such as an antibiotic resistance gene. The vector may be a plasmid.

[0026] The vaccine is advantageously presented in a lyophilised form, for example in a capsular form, for oral ad-

EP 0 574 466 B1

ministration to a patient. Such capsules may be provided with an enteric coating comprising, for example, Eudragate "S", Eudragate "L", Cellulose acetate, cellulose phthalate or hydroxypropylmethyl cellulose. These capsules may be used as such, or alternatively, the lyophilised material may be reconstituted prior to administration, e.g. as a suspension. Reconstitution is advantageously effected in a buffer at a suitable pH to ensure the viability of the organisms. In order to protect the attenuated bacteria and the vaccine from gastric acidity, a sodium bicarbonate preparation is advantageously administered before each administration of the vaccine. Alternatively, the vaccine may be prepared for parenteral administration, intranasal administration or intramammary.

[0027] The attenuated bacterium of the invention may be used in the prophylactic treatment of a host, particularly a human host but also possibly an animal host. An infection caused by a microorganism, especially a pathogen, may therefore be prevented by administering an effective dose of an attenuated bacterium according to the invention. The bacterium then expresses a heterologous protein capable of raising antibody to the microorganism. The dosage employed will be dependent on various factors including the size and weight of the host, the type of vaccine formulated and the nature of the heterologous protein. However, for attenuated *S.typhi* a dosage comprising the oral administration of from 10^9 to 10^{11} *S.typhi* organisms per dose is generally convenient for a 70kg adult human host.

[0028] The following Example illustrates the invention. In the accompanying drawings:

[0029] Figures 1 to 4 show the abilities of isolates of *S.typhimurium* to grow *in vivo* in the liver, spleen, Peyers patches and mesenteric lymph nodes respectively of BALB/c mice. The x-axis denotes days after infection, the y-axis denotes \log_{10} viable organisms per organ, Δ denotes isolate BRD509, \square denotes isolate BRD847, \circ denotes isolate BRD743, — denotes no ampicillin and ---- denotes ampicillin added.

[0030] Figure 5 shows anti-tetanus toxin fragment C titres of mouse sera. The x-axis shows the types of bacteria used to challenge the mice. The number of doses is shown in brackets. The y-axis denotes absorbance readings at 492nm.

EXAMPLEConstruction of pTETnir15

[0031] Expression plasmid pTETnir15 was constructed from pTETtac115 (Makoff *et al*, Nucl. Acids Res. 17 10191-10202, 1989) by replacing the EcoRI-ApaI region (1354bp) containing the lacI gene and lac promoter with the following pair of oligos 1 and 2:

Oligo-1 5'-AATTCAGGTAAATTTGATGTACATCAAATGGTACCCCTTGCTGAATC
Oligo-2 3'-GTCCATTTAAACTACATGTAGTTTACCATGGGGAACGACTTAG
GTTAAGGTAGGCGGTAGGGCC-3'
CAATTCCATCCGCCATC-5'

[0032] The oligonucleotides were synthesized on a Pharmacia Gene Assembler and the resulting plasmids confirmed by sequencing (Makoff *et al*, Bio/Technology 7, 1043-1046, 1989).

Construction of SL1334 aroA aroD harbouring pTETnir15

[0033] In order to construct a *Salmonella* vaccine strain expressing tetanus toxin fragment C under the control of the nirB promoter, an intermediate strain, *S.typhimurium* LB5010 (rm⁺) (Bullas and Ryo, J. Bact. 156, 471-474, 1983), was transformed with pTETnir15. Colonies expressing fragment C were detected by antibiotic selection followed by colony immunoblotting with anti-tetanus toxin fragment C sera. Colonies were grown overnight on nitrocellulose filters aerobically and then induced by incubating under anaerobic conditions for four hours prior to immunoblotting. One strain that was stably expressing fragment C was used to prepare plasmid DNA. This was used to transform an isolate of *S.typhimurium* SL1344 aroA aroD designated BRD509 by electroporation. A strain that was stably expressing fragment C (checked by immunoblotting as described above) was chosen for the *in vivo* studies and was designated BRD 847.

Comparison of *in vivo* kinetics of BRD743 and BRD847 in BALB/c mice

[0034] The ability of BRD743 (BRD509 harbouring pTET85) and of BRD847 to grow *in vivo* was compared after oral administration to BALB/c mice. pTET85 was constructed from pTETtac115 (Makoff *et al*, Nucl. Acids Res. 17,

EP 0 574 466 B1

10191-10202, 1989) by deleting the 1.2kb EcoRI fragment carrying the lacI gene. This resulted in the constitutive expression of fragment C in Salmonella strains. Numbers of bacteria were enumerated in livers, spleens, Peyers patches and mesenteric lymph nodes. The bacteria isolated from mice were also assessed for their ability to grow on plates containing ampicillin as an indicator of the percentage of organisms still retaining the plasmid expressing fragment C. The results are shown in Figures 1 to 4.

[0035] When similar initial numbers of organisms (5×10^9) were used to infect mice it was found that both BRD743 and 847 were able to invade into and persist in all the murine tissues examined but at a lower level than BRD509. However, the interesting feature is that the number of ampicillin resistant organisms obtained from mice infected with BRD743 decreases rapidly and all organisms recovered were ampicillin sensitive by day 14. This indicates that in vivo selection rapidly results in the loss of pTET85 from the Salmonella vaccine strain. In contrast, counts with and without ampicillin for BRD847 were essentially the same for the time the infections were monitored. This demonstrates the added advantage of pTETnir15 in the S.typhimurium vaccine strain resulting in organisms with the potential to express fragment C in vivo for a longer period of time with obvious advantages in terms of immunogenicity.

Immunisation of BALB/c mice using Salmonella strains harbouring pTET85 (BRD743) or pTETnir15 (BRD847)

[0036] Groups of twenty mice were incubated orally with 5×10^9 cells per mouse of either BRD743, BRD847 or BRD509. On day 25 sera were collected from all mice and analysed by ELISA for anti-tetanus antibodies. All mice vaccinated with BRD847 had detectable anti-fragment C antibody at 25 days whereas those vaccinated with BRD743 or BRD509 did not (Fig. 5). On day 25 ten mice from each group were boosted by oral inoculation with a similar amount of homologous organisms. ELISA analysis of the serum taken from these mice at day 46 showed that the anti-fragment C responses had been boosted for groups inoculated with BRD743 and BRD847. The titres for those mice boosted with BRD847 was significantly higher than for those mice boosted with BRD743. Mice boosted orally with BRD509 failed to produce a detectable antibody response to fragment C.

Tetanus toxin challenge of mice orally immunised with BRD847 and 743

[0037] The mice vaccinated orally with BRD743, 847 and 509 were tested for immunity against tetanus toxin challenge after one or two doses of the immunising strain. Groups of twenty mice received one single oral dose of 5×10^9 organisms and groups of ten mice were challenged on day 25 with 500 50% lethal doses of tetanus toxin (see Table 1). Mice vaccinated with BRD847 were completely protected against challenge after a single oral dose whereas those vaccinated with BRD743 were only partially protected (2/10 survivors). The remaining groups of 10 mice received a second dose of organisms (5×10^9) on day 25 and were challenged on day 46 (after the 1st dose). Again mice immunised with BRD847 were completely protected after challenge with tetanus toxin whereas those immunised with BRD743 were only partially protected (5/10). Mice immunised with 1 or 2 doses of BRD509 and challenged with tetanus toxin all died. BRD847 is an effective single dose oral vaccine against tetanus toxin challenge in mice. Groups of mice were also challenged with tetanus toxin after receiving 1 and 2 intravenous doses of 10^5 organisms of BRD847 and BRD743. All mice were fully protected against challenge with tetanus toxin after 1 or 2 doses of vaccine strain.

TABLE 1

Oral immunisation of mice against tetanus using <u>S.typhimurium</u> SL1344 aroA aroD pTET85 and <u>S.typhimurium</u> SL1344 aroA aroD pTETnir15			
Vaccine	Dose	No. Doses	No. of mice surviving tetanus challenge
SL1344 aroA aroD (BRD509)	8.6×10^9	1	0/10
	7.4×10^9	2	0/10
SL1344 aroA aroD pTET85(BRD743)	6.4×10^9	1	2/10
	8.2×10^9	2	5/10
SL1344 aroA aroD pTETnir15(BRD847)	9.5×10^9	1	10/10
	7.5×10^9	2	9/9

EP 0 574 466 B1**Claims****Claims for the following Contracting States : AT, BE, CH, DE, DK, FR, GB, IT, LU, MC, NL, SE**

1. A vaccine comprising a pharmaceutically acceptable carrier or diluent and, as active ingredient, an attenuated bacterium which contains a promoter whose activity is induced by anaerobic conditions operably linked to a DNA sequence encoding a heterologous protein comprising an antigenic determinant of a pathogenic organism.
2. A vaccine according to claim 1, wherein the attenuated bacterium is an attenuated strain of Salmonella.
3. A vaccine according to claim 2, wherein the attenuated bacterium is an attenuated strain of Salmonella typhi or Salmonella typhimurium.
4. A vaccine according to any one of the preceding claims, in which attenuation of the bacterium is attributable to a non-reverting mutation in a gene in the aromatic amino acid biosynthetic pathway.
5. A vaccine according to any one of the preceding claims, in which attenuation of the bacterium is attributable to a non-reverting mutation in DNA of the bacterium which encodes a protein that is produced in response to environmental stress, or in DNA of the bacterium which encodes a protein that regulates the expression of DNA encoding a protein that is produced in response to environmental stress.
6. A vaccine according to claim 4, wherein the attenuated bacterium harbours a non-reverting mutation in each of two discrete genes in its aromatic amino acid biosynthetic pathway.
7. A vaccine according to claim 6, wherein the attenuated bacterium is an aroA aroC, aroA aroD or aroA aroE mutant.
8. A vaccine according to any one of the preceding claims, wherein the promoter contained in the bacterium is the nirB promoter.
9. A vaccine according to any one of the preceding claims, wherein the heterologous protein coding sequence contained in the bacterium codes for an antigenic sequence derived from a virus, bacterium, fungus, yeast or parasite.
10. A vaccine according to claim 9, wherein the heterologous protein coding sequence codes for the P69 protein from Bordetella pertussis or tetanus toxin fragment C.
11. An attenuated bacterium as defined in any one of the preceding claims, for use in a method for prophylactically treating a human or animal host against infection by a microorganism.
12. An attenuated Salmonella bacterium as defined in any one of claims 2 to 10.

Claims for the following Contracting States : ES, GR

1. A method for producing a vaccine, comprising mixing a pharmaceutically acceptable carrier or diluent and, as active ingredient, an attenuated bacterium which contains a promoter whose activity is induced by anaerobic conditions operably linked to a DNA sequence encoding a heterologous protein comprising an antigenic determinant of a pathogenic organism.
2. A method according to claim 1, wherein the attenuated bacterium is an attenuated strain of Salmonella.
3. A method according to claim 2, wherein the attenuated bacterium is an attenuated strain of Salmonella typhi or Salmonella typhimurium.
4. A method according to any one of the preceding claims, in which attenuation of the bacterium is attributable to a non-reverting mutation in a gene in the aromatic amino acid biosynthetic pathway.
5. A method according to any one of the preceding claims, in which attenuation of the bacterium is attributable to a

EP 0 574 466 B1

non-reverting mutation in DNA of the bacterium which encodes a protein that is produced in response to environmental stress, or in DNA of the bacterium which encodes a protein that regulates the expression of DNA encoding a protein that is produced in response to environmental stress.

- 5 6. A method according to claim 4, wherein the attenuated bacterium harbours a non-reverting mutation in each of two discrete genes in its aromatic amino acid biosynthetic pathway.
7. A method according to claim 6, wherein the attenuated bacterium is an aroA aroC, aroA aroD or aroA aroE mutant.
- 10 8. A method according to any one of the preceding claims, wherein the promoter contained in the bacterium is the nirB promoter.
9. A method according to any one of the preceding claims, wherein the heterologous protein coding sequence contained in the bacterium codes for an antigenic sequence derived from a virus, bacterium, fungus, yeast or parasite.
- 15 10. A method according to claim 9, wherein the heterologous protein coding sequence codes for the P69 protein from Bordetella pertussis or tetanus toxin fragment C.
- 20 11. A vaccine comprising a pharmaceutically acceptable carrier or diluent and, as active ingredient, an attenuated bacterium which contains a promoter whose activity is induced by anaerobic conditions operably linked to a DNA sequence encoding a heterologous protein comprising an antigenic determinant of a pathogenic organism.
12. A vaccine according to claim 11, wherein the attenuated bacterium is an attenuated strain of Salmonella.
- 25 13. A vaccine according to claim 12, wherein the attenuated bacterium is an attenuated strain of Salmonella typhi or Salmonella typhimurium.
14. A vaccine according to any one of claims 11 to 13, in which attenuation of the bacterium is attributable to a non-reverting mutation in a gene in the aromatic amino acid biosynthetic pathway.
- 30 15. A vaccine according to any one of claims 11 to 14, in which attenuation of the bacterium is attributable to a non-reverting mutation in DNA of the bacterium which encodes a protein that is produced in response to environmental stress, or in DNA of the bacterium which encodes a protein that regulates the expression of DNA encoding a protein that is produced in response to environmental stress.
- 35 16. A vaccine according to claim 14, wherein the attenuated bacterium harbours a non-reverting mutation in each of two discrete genes in its aromatic amino acid biosynthetic pathway.
- 40 17. A vaccine according to claim 16, wherein the attenuated bacterium is an aroA aroC, aroA aroD or aroA aroE mutant.
18. A vaccine according to any one of claims 11 to 17, wherein the promoter contained in the bacterium is the nirB promoter.
- 45 19. A vaccine according to any one of claims 11 to 18, wherein the heterologous protein coding sequence contained in the bacterium codes for an antigenic sequence derived from a virus, bacterium, fungus, yeast or parasite.
20. A vaccine according to claim 19, wherein the heterologous protein coding sequence codes for the P69 protein from Bordetella pertussis or tetanus toxin fragment C.
- 50 21. An attenuated bacterium as defined in any one of claims 11 to 20, for use in a method for prophylactically treating a human or animal host against infection by a microorganism.
22. An attenuated Salmonella bacterium as defined in any one of claims 12 to 20.

55

EP 0 574 466 B1**Patentansprüche****Patentansprüche für folgende Vertragsstaaten : AT, BE, CH, DE, DK, FR, GB, IT, LU, MC, NL, SE**

1. Impfstoff, umfassend einen pharmazeutisch akzeptablen Träger oder Verdünnungsmittel und, als Wirkstoff, ein abgeschwächtes Bakterium, das einen Promotor enthält, dessen Aktivität durch anaerobe Bedingungen induziert wird, der funktionsfähig an eine DNA-Sequenz gebunden ist, die ein heterologes Protein kodiert, das eine antigenische Determinante eines pathogenen Organismus umfaßt.
2. Impfstoff gemäß Anspruch 1, worin das abgeschwächte Bakterium ein abgeschwächter Stamm von *Salmonella* ist.
3. Impfstoff gemäß Anspruch 2, worin das abgeschwächte Bakterium ein abgeschwächter Stamm von *Salmonella typhi* oder *Salmonella typhimurium* ist.
4. Impfstoff gemäß einem der vorhergehenden Ansprüche, worin die Abschwächung des Bakteriums einer nicht-umkehrenden Mutation in einem Gen im aromatischen Aminosäure-Biosyntheseweg zuschreibbar ist.
5. Impfstoff gemäß einem der vorhergehenden Ansprüche, worin die Abschwächung des Bakteriums einer nicht-umkehrenden Mutation in der DNA des Bakteriums zuschreibbar ist, die ein Protein kodiert, das als Reaktion auf Umweltbelastung erzeugt wird, oder in der DNA des Bakteriums, die ein Protein kodiert, das die Expression von DNA reguliert, die ein Protein kodiert, das als Antwort auf Umweltbelastung erzeugt wird.
6. Impfstoff gemäß Anspruch 4, worin das abgeschwächte Bakterium eine nicht-umkehrende Mutation in jedem von zwei diskreten Genen in seinem aromatischen Aminosäure-Biosyntheseweg beherbergt.
7. Impfstoff gemäß Anspruch 6, worin das abgeschwächte Bakterium eine *aroA aroC*-, *aroA aroD*- oder *aroA aroE*-Mutante ist.
8. Impfstoff gemäß einem der vorhergehenden Ansprüche, worin der im Bakterium enthaltene Promotor der *nirB*-Promotor ist.
9. Impfstoff gemäß einem der vorhergehenden Ansprüche, worin die im Bakterium enthaltene heterologe Protein-Kodierungssequenz eine antigenische Sequenz kodiert, die aus einem Virus, Bakterium, Pilz, einer Hefe oder einem Parasiten stammt.
10. Impfstoff gemäß Anspruch 9, worin die heterologe Protein-Kodierungssequenz das P69-Protein aus *Bordetella pertussis* oder Tetanustoxin-Fragment C kodiert.
11. Abgeschwächtes Bakterium, wie in einem der vorhergehenden Ansprüche definiert, zur Verwendung in einem Verfahren zur prophylaktischen Behandlung eines menschlichen oder tierischen Wirts gegen Infektion durch einen Mikroorganismus.
12. Abgeschwächtes *Salmonella*-Bakterium, wie in einem der Ansprüche 2 bis 10 definiert.

Patentansprüche für folgende Vertragsstaaten : ES, GR

1. Verfahren zur Herstellung eines Impfstoffs, umfassend das Vermischen eines pharmazeutisch akzeptablen Trägers oder Verdünnungsmittels und, als Wirkstoff, eines abgeschwächten Bakteriums, das einen Promotor enthält, dessen Aktivität durch anaerobe Bedingungen induziert wird, der funktionsfähig an eine DNA-Sequenz gebunden ist, die ein heterologes Protein kodiert, das eine antigenische Determinante eines pathogenen Organismus umfaßt.
2. Verfahren gemäß Anspruch 1, worin das abgeschwächte Bakterium ein abgeschwächter Stamm von *Salmonella* ist.
3. Verfahren gemäß Anspruch 2, worin das abgeschwächte Bakterium ein abgeschwächter Stamm von *Salmonella typhi* oder *Salmonella typhimurium* ist.

EP 0 574 466 B1

4. Verfahren gemäß einem der vorhergehenden Ansprüche, worin die Abschwächung des Bakteriums einer nicht-umkehrenden Mutation in einem Gen im aromatischen Aminosäure-Biosyntheseweg zuschreibbar ist.
- 5 5. Verfahren gemäß einem der vorhergehenden Ansprüche, worin die Abschwächung des Bakteriums einer nicht-umkehrenden Mutation in der DNA des Bakteriums zuschreibbar ist, die ein Protein kodiert, das als Antwort auf Umweltbelastung erzeugt wird, oder in der DNA des Bakteriums, die ein Protein kodiert, das die Expression von DNA reguliert, die ein Protein kodiert, das als Antwort auf Umweltbelastung erzeugt wird.
- 10 6. Verfahren gemäß Anspruch 4, worin das abgeschwächte Bakterium eine nicht-umkehrende Mutation in jedem von zwei diskreten Genen in seinem aromatischen Aminosäure-Biosyntheseweg beherbergt.
7. Verfahren gemäß Anspruch 6, worin das abgeschwächte Bakterium eine aroA aroC-, aroA aroD- oder aroA aroE-Mutante ist.
- 15 8. Verfahren gemäß einem der vorhergehenden Ansprüche, worin der im Bakterium enthaltene Promotor der nirB-Promotor ist.
9. Verfahren gemäß einem der vorhergehenden Ansprüche, worin die im Bakterium enthaltene heterologe Protein-Kodierungssequenz eine antigenische Sequenz kodiert, die aus einem Virus, Bakterium, Pilz, einer Hefe oder
20 einem Parasiten stammt.
10. Verfahren gemäß Anspruch 9, worin die heterologe Protein-Kodierungssequenz das P69-Protein aus Bordetella pertussis oder Tetanustoxin-Fragment C kodiert.
- 25 11. Impfstoff, umfassend einen pharmazeutisch akzeptablen Träger oder Verdünnungsstoff und, als Wirkstoff, ein abgeschwächtes Bakterium, das einen Promotor enthält, dessen Aktivität durch anaerobe Bedingungen induziert wird, der funktionsfähig an eine DNA-Sequenz gebunden ist, die ein heterologes Protein kodiert, das eine antigenische Determinante eines pathogenen Organismus umfaßt.
- 30 12. Impfstoff gemäß Anspruch 11, worin das abgeschwächte Bakterium ein abgeschwächter Stamm von Salmonella ist.
13. Impfstoff gemäß Anspruch 12, worin das abgeschwächte Bakterium ein abgeschwächter Stamm von Salmonella typhi oder Salmonella typhimurium ist.
- 35 14. Impfstoff gemäß einem der Ansprüche 11 bis 13, worin die Abschwächung des Bakteriums einer nicht-umkehrenden Mutation in einem Gen im aromatischen Aminosäure-Biosyntheseweg zuschreibbar ist.
- 40 15. Impfstoff gemäß einem der Ansprüche 11 bis 14, worin die Abschwächung des Bakteriums einer nicht-umkehrenden Mutation in der DNA des Bakteriums zuschreibbar ist, die ein Protein kodiert, das als Reaktion auf Umweltbelastung erzeugt wird, oder in der DNA des Bakteriums, die ein Protein kodiert, das die Expression von DNA reguliert, die ein Protein kodiert, das als Antwort auf Umweltbelastung erzeugt wird.
- 45 16. Impfstoff gemäß Anspruch 14, worin das abgeschwächte Bakterium eine nicht-umkehrende Mutation in jedem von zwei diskreten Genen in seinem aromatischen Aminosäure-Biosyntheseweg beherbergt.
17. Impfstoff gemäß Anspruch 16, worin das abgeschwächte Bakterium eine aroA aroC-, aroA aroD- oder aroA aroE-Mutante ist.
- 50 18. Impfstoff gemäß einem der Ansprüche 11 bis 17, worin der im Bakterium enthaltene Promotor der nirB-Promotor ist.
19. Impfstoff gemäß einem der Ansprüche 11 bis 18, worin die im Bakterium enthaltene heterologe Protein-Kodierungssequenz eine antigenische Sequenz kodiert, die aus einem Virus, Bakterium, Pilz, einer Hefe oder einem
55 Parasiten stammt.
20. Impfstoff gemäß Anspruch 19, worin die heterologe Protein-Kodierungssequenz das P69-Protein aus Bordetella pertussis oder Tetanustoxin-Fragment C kodiert.

EP 0 574 466 B1

21. Abgeschwächtes Bakterium, wie in einem der Ansprüche 11 bis 20 definiert, zur Verwendung in einem Verfahren zur prophylaktischen Behandlung eines menschlichen oder tierischen Wirts gegen Infektion durch einen Mikroorganismus.

5 22. Abgeschwächtes Salmonella-Bakterium, wie in einem der Ansprüche 12 bis 20 definiert.

Revendications

10

Revendications pour les Etats contractants suivants : AT, BE, CH, DE, DK, FR, GB, IT, LU, MC, NL, SE

15

1. Vaccin comprenant un support ou diluant acceptable d'un point de vue pharmaceutique et, en tant que principe actif, une bactérie atténuée qui contient un promoteur dont l'activité est induite par des conditions anaérobies, lié de manière opérationnelle à une séquence d'ADN codant une protéine hétérologue comprenant un déterminant antigénique d'un organisme pathogène.

2. Vaccin selon la revendication 1, dans lequel la bactérie atténuée est une souche atténuée de Salmonella.

20

3. Vaccin selon la revendication 2, dans lequel la bactérie atténuée est une souche atténuée de Salmonella typhi ou Salmonella typhimurium.

4. Vaccin selon l'une quelconque des revendications précédentes, dans lequel l'atténuation de la bactérie est attribuable à une mutation non-réverse dans un gène de la voie de biosynthèse des acides aminés aromatiques.

25

5. Vaccin selon l'une quelconque des revendications précédentes, dans lequel l'atténuation de la bactérie est attribuable à une mutation non-réverse dans l'ADN de la bactérie qui code une protéine qui est produite en réponse à une agression de l'extérieur, ou dans l'ADN de la bactérie qui code une protéine qui régule l'expression de l'ADN codant une protéine qui est produite en réponse à une agression de l'extérieur.

30

6. Vaccin selon la revendication 4, dans lequel la bactérie atténuée présente une mutation non-réverse dans chacun de deux gènes discrets de sa voie de biosynthèse des acides aminés aromatiques.

7. Vaccin selon la revendication 6, dans lequel la bactérie atténuée est un mutant aroA aroC, aroA aroD ou aroA aroE.

35

8. Vaccin selon l'une quelconque des revendications précédentes, dans lequel le promoteur contenu dans la bactérie est le promoteur nirB.

9. Vaccin selon l'une quelconque des revendications précédentes, dans lequel la séquence codant la protéine hétérologue, contenue dans la bactérie, code pour une séquence antigénique qui dérive d'un virus, d'une bactérie, d'un champignon, d'une levure ou d'un parasite.

40

10. Vaccin selon la revendication 9, dans lequel la séquence codant la protéine hétérologue code pour la protéine P69 de Bordetella pertussis ou du fragment C de la toxine du tétanos.

45

11. Bactérie atténuée selon l'une quelconque des revendications précédentes, pour utilisation dans un procédé de traitement prophylactique d'un hôte humain ou animal vis-à-vis d'une infection par un micro-organisme.

12. Bactérie Salmonella atténuée telle que définie selon l'une quelconque des revendications 2 à 10.

50

Revendications pour les Etats contractants suivants : ES, GR

55

1. Procédé de production d'un vaccin, qui consiste à mélanger un support ou diluant acceptable d'un point de vue pharmaceutique et, en tant que principe actif, une bactérie atténuée qui contient un promoteur dont l'activité est induite par des conditions anaérobies, lié de manière opérationnelle à une séquence d'ADN codant une protéine hétérologue comprenant un déterminant antigénique d'un organisme pathogène.

EP 0 574 466 B1

2. Procédé selon la revendication 1, dans lequel la bactérie atténuée est une souche atténuée de Salmonella.
3. Procédé selon la revendication 2, dans lequel la bactérie atténuée est une souche atténuée de Salmonella typhi ou Salmonella typhimurium.
- 5 4. Procédé selon l'une quelconque des revendications précédentes, dans lequel l'atténuation de la bactérie est attribuable à une mutation non-réversible dans un gène de la voie de biosynthèse des acides aminés aromatiques.
- 10 5. Procédé selon l'une quelconque des revendications précédentes, dans lequel l'atténuation de la bactérie est attribuable à une mutation non-réversible dans l'ADN de la bactérie qui code une protéine qui est produite en réponse à une agression de l'extérieur, ou dans l'ADN de la bactérie qui code une protéine qui régule l'expression de l'ADN codant une protéine qui est produite en réponse à une agression de l'extérieur.
- 15 6. Procédé selon la revendication 4, dans lequel la bactérie atténuée présente une mutation non-réversible dans chacun de deux gènes discrets de sa voie de biosynthèse des acides aminés aromatiques.
7. Procédé selon la revendication 6, dans lequel la bactérie atténuée est un mutant aroA aroC, aroA aroD ou aroA aroE.
- 20 8. Procédé selon l'une quelconque des revendications précédentes, dans lequel le promoteur contenu dans la bactérie est le promoteur nirB.
9. Procédé selon l'une quelconque des revendications précédentes, dans lequel la séquence codant la protéine hétérologue, contenue dans la bactérie, code pour une séquence antigénique qui dérive d'un virus, d'une bactérie, d'un champignon, d'une levure ou d'un parasite.
- 25 10. Procédé selon la revendication 9, dans lequel la séquence codant la protéine hétérologue code pour la protéine P69 de Bordetella pertussis ou du fragment C de la toxine du tétanos.
- 30 11. Vaccin comprenant un support ou diluant acceptable d'un point de vue pharmaceutique et, en tant que principe actif, une bactérie atténuée qui contient un promoteur dont l'activité est induite par des conditions anaérobies, lié de manière opérationnelle à une séquence d'ADN codant une protéine hétérologue comprenant un déterminant antigénique d'un organisme pathogène.
- 35 12. Vaccin selon la revendication 11, dans lequel la bactérie atténuée est une souche atténuée de Salmonella.
13. Vaccin selon la revendication 12, dans lequel la bactérie atténuée est une souche atténuée de Salmonella typhi ou Salmonella typhimurium.
- 40 14. Vaccin selon l'une quelconque des revendications 11 à 13, dans lequel l'atténuation de la bactérie est attribuable à une mutation non-réversible dans un gène de la voie de biosynthèse des acides aminés aromatiques.
15. Vaccin selon l'une quelconque des revendications 11 à 14, dans lequel l'atténuation de la bactérie est attribuable à une mutation non-réversible dans l'ADN de la bactérie qui code une protéine qui est produite en réponse à une agression de l'extérieur, ou dans l'ADN de la bactérie qui code une protéine qui régule l'expression de l'ADN codant une protéine qui est produite en réponse à une agression de l'extérieur.
- 45 16. Vaccin selon la revendication 14, dans lequel la bactérie atténuée présente une mutation non-réversible dans chacun de deux gènes discrets de sa voie de biosynthèse des acides aminés aromatiques.
- 50 17. Vaccin selon la revendication 16, dans lequel la bactérie atténuée est un mutant aroA aroC, aroA aroD ou aroA aroE.
18. Vaccin selon l'une quelconque des revendications 11 à 17, dans lequel le promoteur contenu dans la bactérie est le promoteur nirB.
- 55 19. Vaccin selon l'une quelconque des revendications 11 à 18, dans lequel la séquence codant la protéine hétérologue, contenue dans la bactérie, code pour une séquence antigénique qui dérive d'un virus, d'une bactérie, d'un cham-

EP 0 574 466 B1



pignon, d'une levure ou d'un parasite.

20. Vaccin selon la revendication 19, dans lequel la séquence codant la protéine hétérologue code pour la protéine P69 de Bordetella pertussis ou du fragment C de la toxine du tétanos.



21. Bactérie atténuée selon l'une quelconque des revendications 11 à 20, pour utilisation dans un procédé de traitement prophylactique d'un hôte humain ou animal vis-à-vis d'une infection par un micro-organisme.

22. Bactérie Salmonella atténuée telle que définie selon l'une quelconque des revendications 12 à 20.


EP 0 574 466 B1

Fig. 1.*Fig. 2.*

EP 0 574 466 B1

Fig.3.*Fig.4.*

EP 0 574 466 B1

Fig. 5.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.